Stock ANN ANSELL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ansell Limited

Equities

ANN

AU000000ANN9

Medical Equipment, Supplies & Distribution

Delayed Australian S.E.
Other stock markets
 11:42:52 2024-04-28 pm EDT 		5-day change 1st Jan Change
25.29 AUD -0.04% Intraday chart for Ansell Limited +0.20% +0.44%
Apr. 15 Ansell Launches AU$65 Million Share Purchase Plan MT
Apr. 10 JPMorgan Upgrades Ansell to Overweight from Neutral, Price Target is AU$29.20 MT

Valuation

Fiscal Period: Junio 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 2,493 3,255 4,176 1,936 2,243 2,332 - -
Enterprise Value (EV) 1 2,621 3,426 4,456 2,157 2,494 2,597 2,789 2,706
P/E ratio 23.2 x 20.8 x 17 x 12.4 x 15.2 x 28.5 x 14.5 x 11.9 x
Yield 2.48% 1.97% 2.35% 3.62% 2.58% 2.31% 2.78% 3.35%
Capitalization / Revenue 1.66 x 2.02 x 2.06 x 0.99 x 1.36 x 1.43 x 1.22 x 1.14 x
EV / Revenue 1.75 x 2.12 x 2.2 x 1.1 x 1.51 x 1.59 x 1.46 x 1.33 x
EV / EBITDA 10.9 x 12.4 x 11.1 x 6.95 x 9.09 x 10.4 x 8.37 x 7.01 x
EV / FCF 18 x 15.2 x 48.2 x 14 x 22 x 15.8 x 19.8 x 16.8 x
FCF Yield 5.54% 6.6% 2.07% 7.16% 4.54% 6.34% 5.04% 5.97%
Price to Book 1.77 x 2.35 x 2.69 x 1.27 x 1.41 x 1.17 x 1.16 x 1.09 x
Nbr of stocks (in thousands) 132,303 128,527 128,006 126,262 126,007 141,315 - -
Reference price 2 18.84 25.32 32.62 15.34 17.80 16.50 16.50 16.50
Announcement Date 8/11/19 8/24/20 8/23/21 8/22/22 8/13/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Junio 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,499 1,614 2,027 1,952 1,655 1,631 1,916 2,040
EBITDA 1 241 276.2 402.1 310.4 274.3 248.8 333.1 385.9
EBIT 1 202.8 219.7 338 245.1 206.3 174.5 256.3 305.5
Operating Margin 13.53% 13.61% 16.68% 12.56% 12.46% 10.7% 13.37% 14.97%
Earnings before Tax (EBT) 1 143.7 202.3 318.1 208.4 189.6 147.1 215.6 271.3
Net income 1 111.7 158.7 246.7 158.7 148.3 81.03 157 196.8
Net margin 7.45% 9.83% 12.17% 8.13% 8.96% 4.97% 8.19% 9.65%
EPS 2 0.8120 1.218 1.922 1.238 1.175 0.5780 1.137 1.385
Free Cash Flow 1 145.3 226.1 92.4 154.5 113.3 164.5 140.5 161.5
FCF margin 9.69% 14.01% 4.56% 7.91% 6.85% 10.09% 7.33% 7.92%
FCF Conversion (EBITDA) 60.29% 81.86% 22.98% 49.77% 41.31% 66.12% 42.18% 41.85%
FCF Conversion (Net income) 130.08% 142.47% 37.45% 97.35% 76.4% 203.06% 89.47% 82.05%
Dividend per Share 2 0.4675 0.5000 0.7680 0.5545 0.4590 0.3819 0.4585 0.5522
Announcement Date 8/11/19 8/24/20 8/23/21 8/22/22 8/13/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2020 S1 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 753.3 860.4 937.8 1,089 1,009 942.9 835.3 819.8 784.9 836.8
EBITDA 119.7 156.5 178 224.1 143.6 166.8 125.2 149.1 114.4 -
EBIT 1 91.8 127.9 147.4 190.6 111 134.1 91.5 - 78.2 98.9
Operating Margin 12.19% 14.87% 15.72% 17.5% 11% 14.22% 10.95% - 9.96% 11.82%
Earnings before Tax (EBT) - 118.4 137.4 180.7 100.9 107.5 82.3 - - -
Net income 65.8 92.9 106.5 140.2 77.2 81.5 63.9 84.4 19.4 -
Net margin 8.73% 10.8% 11.36% 12.87% 7.65% 8.64% 7.65% 10.3% 2.47% -
EPS - 0.7240 0.8290 1.093 0.5990 0.6390 0.5030 - 0.1540 -
Dividend per Share 2 0.2175 0.2825 0.3320 0.4360 0.5560 0.3120 0.2010 0.2580 0.1650 0.2300
Announcement Date 2/17/20 8/24/20 2/15/21 8/23/21 2/14/22 8/22/22 2/13/23 8/13/23 2/19/24 -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 128 171 280 220 251 265 457 375
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 0.5303 x 0.6206 x 0.6961 x 0.7091 x 0.9132 x 1.066 x 1.372 x 0.9711 x
Free Cash Flow 1 145 226 92.4 155 113 165 141 162
ROE (net income / shareholders' equity) 10.2% 11.4% 16.8% 10.2% 9.1% 6.82% 8.53% 9.7%
ROA (Net income/ Total Assets) 6.16% 6.58% 9.53% 6.05% 5.8% 4.72% 6.27% 7.04%
Assets 1 1,813 2,413 2,588 2,623 2,555 1,715 2,504 2,796
Book Value Per Share 2 10.70 10.80 12.10 12.10 12.60 14.10 14.20 15.20
Cash Flow per Share 2 1.370 2.200 1.330 1.730 1.420 2.180 1.610 1.770
Capex 1 43.6 64.8 80.4 67.5 67.2 77.2 80.7 83.9
Capex / Sales 2.91% 4.02% 3.97% 3.46% 4.06% 4.74% 4.21% 4.11%
Announcement Date 8/11/19 8/24/20 8/23/21 8/22/22 8/13/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Ansell Limited

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
16.5 USD
Average target price
17.78 USD
Spread / Average Target
+7.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
ANSELL LIMITED Stock Ansell Limited
+0.48% 2.33B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. ANN Stock
  4. Financials Ansell Limited